Pancreatic cancer remains one of medicine's most stubborn adversaries, with five-year survival rates below 12% and limited treatment breakthroughs over decades. This changes the conversation by demonstrating meaningful clinical activity against RAS mutations—genetic alterations present in over 90% of pancreatic tumors that have long been considered "undruggable."
Daraxonrasib, an oral RAS(ON) multiselective inhibitor, achieved objective responses in 35% of patients with specific G12 mutations when used as second-line therapy at 300mg daily. Among 168 previously treated patients, the drug showed manageable toxicity profiles, with 96% experiencing treatment-related side effects but only 30% reporting severe events. Common reactions included rash, diarrhea, and fatigue. The 8.2-month median response duration and 13.1-month overall survival represent substantial improvements for this patient population.
This represents a potential paradigm shift in targeting RAS proteins, which drive roughly one-third of all human cancers. Unlike previous attempts that focused on blocking RAS activation, daraxonrasib targets the active, GTP-bound form of mutant RAS proteins. The specificity for G12 mutations—the most common RAS alteration in pancreatic cancer—suggests precision medicine applications may finally be viable for this disease.
However, the 26-patient subgroup analysis requires cautious interpretation pending larger phase 3 trials. The drug's broad RAS inhibition could theoretically affect normal cellular functions, though early safety data appears manageable. If confirmed in larger studies, this approach could extend beyond pancreatic cancer to other RAS-driven malignancies, potentially revolutionizing treatment for millions of patients with historically intractable cancers.